BR0210898A - Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril - Google Patents
Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estérilInfo
- Publication number
- BR0210898A BR0210898A BR0210898-4A BR0210898A BR0210898A BR 0210898 A BR0210898 A BR 0210898A BR 0210898 A BR0210898 A BR 0210898A BR 0210898 A BR0210898 A BR 0210898A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulation
- preparation
- unit dose
- vial
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0116619.8A GB0116619D0 (en) | 2001-07-07 | 2001-07-07 | Formulation |
US31571101P | 2001-08-30 | 2001-08-30 | |
PCT/GB2002/003092 WO2003006064A1 (fr) | 2001-07-07 | 2002-07-03 | Formulation pharmaceutique pour l'administration intramusculaire de fulvestrant |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0210898A true BR0210898A (pt) | 2004-06-22 |
Family
ID=26246290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0210898-4A BR0210898A (pt) | 2001-07-07 | 2002-07-03 | Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1406662A1 (fr) |
JP (1) | JP2004534093A (fr) |
CN (1) | CN1553815A (fr) |
AR (1) | AR037138A1 (fr) |
BR (1) | BR0210898A (fr) |
CA (1) | CA2453111A1 (fr) |
CO (1) | CO5560585A2 (fr) |
HU (1) | HUP0400115A3 (fr) |
IL (1) | IL159576A0 (fr) |
IS (1) | IS7097A (fr) |
MX (1) | MXPA04000028A (fr) |
NO (1) | NO20040047L (fr) |
PL (1) | PL367624A1 (fr) |
RU (1) | RU2004102393A (fr) |
WO (1) | WO2003006064A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
AU2009351590B2 (en) | 2009-07-31 | 2013-07-18 | Xi'an Libang Pharmaceutical Technology Co., Ltd. | Fulvestrant nanosphere/microsphere and preparative method and use thereof |
CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
CN102600073B (zh) | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
CN102600065B (zh) * | 2012-03-31 | 2014-08-13 | 莱普德制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
JP6682163B2 (ja) * | 2016-04-06 | 2020-04-15 | 富士フイルム株式会社 | 医薬組成物 |
CA3022834A1 (fr) * | 2016-05-06 | 2017-11-09 | Eagle Pharmaceuticals, Inc. | Formulations de fulvestrant et methodes d'utilisation de celles-ci |
US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
CN109152785B (zh) | 2016-05-31 | 2021-02-09 | 富士胶片株式会社 | 医药组合物 |
EP3706719A1 (fr) * | 2017-11-08 | 2020-09-16 | Eagle Pharmaceuticals, Inc. | Formulations de fulvestrant et méthodes d'utilisation de ces dernières |
WO2019113361A1 (fr) * | 2017-12-07 | 2019-06-13 | Nevakar Inc. | Compositions de fulvestrant concentré |
WO2019151353A1 (fr) * | 2018-01-31 | 2019-08-08 | 富士フイルム株式会社 | Méthode de production de préparation pour injection |
CN111481559B (zh) * | 2019-01-25 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种高浓度的氟维司群组合物及其制备方法 |
CN113260353A (zh) * | 2019-12-11 | 2021-08-13 | 上海博志研新药物技术有限公司 | 氟维司群药物组合物、其制备方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
GB9525194D0 (en) * | 1995-12-12 | 1996-02-07 | Zeneca Ltd | Pharmaceutical composition |
GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
-
2002
- 2002-07-03 CA CA002453111A patent/CA2453111A1/fr not_active Abandoned
- 2002-07-03 HU HU0400115A patent/HUP0400115A3/hu unknown
- 2002-07-03 JP JP2003511869A patent/JP2004534093A/ja active Pending
- 2002-07-03 IL IL15957602A patent/IL159576A0/xx unknown
- 2002-07-03 RU RU2004102393/15A patent/RU2004102393A/ru not_active Application Discontinuation
- 2002-07-03 BR BR0210898-4A patent/BR0210898A/pt not_active IP Right Cessation
- 2002-07-03 WO PCT/GB2002/003092 patent/WO2003006064A1/fr not_active Application Discontinuation
- 2002-07-03 PL PL02367624A patent/PL367624A1/xx not_active Application Discontinuation
- 2002-07-03 CN CNA028171888A patent/CN1553815A/zh active Pending
- 2002-07-03 EP EP02740940A patent/EP1406662A1/fr not_active Withdrawn
- 2002-07-05 AR ARP020102523A patent/AR037138A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 IS IS7097A patent/IS7097A/is unknown
- 2004-01-06 NO NO20040047A patent/NO20040047L/no not_active Application Discontinuation
- 2004-01-07 CO CO04000761A patent/CO5560585A2/es not_active Application Discontinuation
- 2004-01-07 MX MXPA04000028A patent/MXPA04000028A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2453111A1 (fr) | 2003-01-23 |
EP1406662A1 (fr) | 2004-04-14 |
IL159576A0 (en) | 2004-06-01 |
WO2003006064A1 (fr) | 2003-01-23 |
CO5560585A2 (es) | 2005-09-30 |
IS7097A (is) | 2004-01-05 |
MXPA04000028A (es) | 2004-05-21 |
RU2004102393A (ru) | 2005-03-27 |
HUP0400115A3 (en) | 2005-11-28 |
HUP0400115A2 (hu) | 2004-06-28 |
NO20040047L (no) | 2004-02-23 |
PL367624A1 (en) | 2005-03-07 |
JP2004534093A (ja) | 2004-11-11 |
CN1553815A (zh) | 2004-12-08 |
AR037138A1 (es) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0107445A (pt) | Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco | |
BR0210898A (pt) | Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril | |
ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
AR098109A2 (es) | Un análogo de epotilona, su uso para la preparación de un medicamento y una composición farmacéutica adecuada para administración parenteral | |
BRPI0513673A (pt) | método para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, veìculo utilizado na administração enteral de compostos biologicamente ativos, composição farmacêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
BR0208013A (pt) | Mecanismo de acionamento para um dispositivo de injeção e dispositivo de injeção | |
BR9916829A (pt) | Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol | |
BR9810729A (pt) | Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante | |
KR970704434A (ko) | 약학적으로 안정한 옥살리플라티늄 제제(pharmaceutically stable oxaliplatinum preparation) | |
ES2253423T3 (es) | Formulacion de un ester de testosterona para uso humano. | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
KR970706021A (ko) | N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS) | |
CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
PT1256339E (pt) | Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina | |
BR9706537A (pt) | Composição farmacêutica para administração por via oral | |
BR0210595A (pt) | Regime de dosagem e composição farmacêutica para contracepção de emergência | |
HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
BR9916830A (pt) | Formulações aerossóis farmacêuticas contendo fluoroalcanos e budesonide | |
BR0008713A (pt) | Processos para preparar formulações ecomposições farmacêuticas orais com ecb | |
BR9915215A (pt) | Composição farmacêutica para liberação modificada de sensibilizador de insulina | |
BR9814751A (pt) | Composição sólida seca para liberação de droga, processo para a preparação da mesma, e, uso de um grande número de partìculas porosas inorgânicas que são compostas de hidroxiapatita de cerâmica. | |
KR920703112A (ko) | 의약품 조성물 | |
AR008559A1 (es) | Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo | |
AR045912A1 (es) | Composiciones farmaceuticas que contienen derivados de azetidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |